Delivery of epidrugs

Drug Discovery Today

Volumn 19, Issue 9, 2014, Pages 1337-1352

  El Bahhaj, Fatima ^a   Dekker, Frank J ^b   Martinet, Nadine ^c   Bertrand, Philippe ^a  

^a CNRS   (France)

^b UNIVERSITY OF GRONINGEN   (Netherlands)

^c UNIVERSITÉ DE NICE SOPHIA ANTIPOLIS   (France)

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; ANILINE DERIVATIVE; ANTINEOPLASTIC AGENT; AZACITIDINE; BENZAMIDE DERIVATIVE; CARBOXYLIC ACID; CURCUMIN; DNA METHYLTRANSFERASE 1; GEMCITABINE; HISTONE ACETYLTRANSFERASE PCAF; HISTONE DEACETYLASE; HISTONE DEACETYLASE INHIBITOR; HYDROXAMIC ACID; LYSERGIDE; METHYLTRANSFERASE; NANOPARTICLE; NUCLEOSIDE; POLYNUCLEOTIDE; POLYPHENOL; PRODRUG; PROTEIN; PROTEIN MDM2; QUERCETIN; RESVERATROL; ROMIDEPSIN; SIRTUIN; THIOL; URIDINE;

CANCER THERAPY; CHEMICAL MODIFICATION; CHEMISTRY; CHROMATIN STRUCTURE; DRUG CLEARANCE; DRUG DELIVERY SYSTEM; EPIGENETICS; GENE CONTROL; HUMAN; MOLECULAR MODEL; MOLECULARLY TARGETED THERAPY; NONHUMAN; REVIEW; ANIMAL; DOSE RESPONSE; DRUG DESIGN; GENETIC EPIGENESIS; GENETICS; NEOPLASMS;

ANIMALS; ANTINEOPLASTIC AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG DELIVERY SYSTEMS; DRUG DESIGN; EPIGENESIS, GENETIC; HUMANS; NANOPARTICLES; NEOPLASMS; PRODRUGS;

EID: 84907845714     PISSN: 13596446     EISSN: 18785832     Source Type: Journal    
DOI: 10.1016/j.drudis.2014.03.017     Document Type: Review

References (147)

1. The NIH Roadmap Epigenomics Program. Available at: http://nihroadmap.nih.gov/epigenomics/
2. C.H. Arrowsmith Epigenetic protein families: a new frontier for drug discovery Nat. Rev. Drug Discov. 11 2012 384 400
3. R. Taby, and J.P. Issa Cancer epigenetics CA Cancer J. Clin. 60 2010 376 392
4. B.C. Smith, and J.M. Denu Chemical mechanisms of histone lysine and arginine modifications Biochim. Biophys. Acta 1789 2009 45 57
5. N. Martinet Small molecules DNA methyltransferases inhibitors Med. Chem. Commun. 3 2012 263 273
6. M.M. Suzuki, and A. Bird DNA methylation landscapes: provocative insights from epigenomics Nat. Rev. Genet. 9 2008 465 476
7. C. Loenarz, and C.J. Schofield Oxygenase catalyzed 5-methylcytosine hydroxylation Chem. Biol. 16 2009 580 583
8. C. Gros DNA methylation inhibitors in cancer: recent and future approaches Biochimie 94 2012 2280 2296
9. J.C. Black Histone lysine methylation dynamics: establishment, regulation, and biological impact Mol. Cell 48 2012 491 507
10. Y. Yao Selective inhibitors of histone methyltransferase DOT1L: design, synthesis, and crystallographic studies J. Am. Chem. Soc. 133 2011 16746 16749
11. C. Zagni Histone methyltransferase inhibitors: novel epigenetic agents for cancer treatment Curr. Med. Chem. 20 2013 167 185
12. J. Schneider, and A. Shilatifard Histone demethylation by hydroxylation: chemistry in action ACS Chem. Biol. 1 2006 75 81
13. H. Benelkebir Enantioselective synthesis of tranylcypromine analogues as lysine demethylases (LSD1) inhibitors Bioorg. Med. Chem. 19 2011 3709 3716
14. M. Yang Structural basis of histone demethylation by LSD1 revealed by suicide inactivation Nat. Struct. Mol. Biol. 14 2007 535 539
15. M.T. Bedford, and S.G. Clarke Protein arginine methylation in mammals: who, what, and why Mol. Cell 33 2009 1 13
16. N. Fontán Novel symmetrical ureas as modulators of protein arginine methyl transferases Bioorg. Med. Chem. 21 2013 2056 2067
17. F.J. Dekker, and H.J. Haisma Histone acetyl transferases as emerging drug targets Drug Discov. Today 14 2009 942 948
18. F.M. Perez-Campo The MYSTerious MOZ, a histone acetyltransferase with a key role in haematopoiesis Immunology 139 2013 161 165
19. C.A. Olsen Expansion of the lysine acylation landscape Angew. Chem. Int. Ed. 51 2012 3755 3756
20. M.W. Rekowski, and A. Giannis Histone acetylation modulation by small molecules: a chemical approach Biochim. Biophys. Acta 1799 2010 760 767
21. J.M. Denu The Sir 2 family of protein deacetylases Curr. Opin. Chem. Biol. 9 2005 431 440
22. P. Bertrand Inside HDACs with HDAC inhibitors Eur. J. Med. Chem. 45 2010 2095 2116
23. N. Martinet, and P. Bertrand Interpreting clinical trials for histone deacetylase inhibitors Cancer Manag. Res. 3 2011 117 141
24. H. Maeda Tumor-selective delivery of macromolecular drugs via the EPR effect: background and future prospects Bioconjug. Chem. 21 2010 797 802
25. G. Pasut, and F.M. Veronese Polymer-drug conjugation, recent achievements and general strategies Prog. Polym. Sci. 32 2007 933 961
26. G. Scita, and P.P. Di Fiore The endocytic matrix Nature 463 2010 464 473
27. M. Kirkham, and R.G. Parton Clathrin-independent endocytosis: new insights into caveolae and non-caveolar lipid raft carriers Biochim. Biophys. Acta 1745 2005 273 286
28. E. Jähde, and M.F. Rajewsky Tumor-selective modification of cellular microenvironment in vivo: effect of glucose infusion on the pH in normal and malignant rat tissues Cancer Res. 42 1982 1505 1512
29. P.P. Gullino Glucose consumption by transplanted tumors in vivo Cancer Res. 27 1967 1031 1040
30. D.M. Prescott The relationship between intracellular and extracellular pH in spontaneous canine tumors Clin. Cancer Res. 6 2000 2501 2505
31. S.M. Simon Role of organelle pH in tumor cell biology and drug resistance Drug Discov. Today 4 1999 32 38
32. N.M. Sakhrani, and H. Padh Organelle targeting: third level of drug targeting Drug Des. Dev. Ther. 7 2013 585 599
33. B.M. Liederer, and R.T. Borchardt Enzymes involved in the bioconversion of ester-based prodrugs J. Pharm. Sci. 95 2006 1177 1195
34. P.M. Potter, and R.M. Wadkins Carboxylesterases: detoxifying enzymes and targets for drug therapy Curr. Med. Chem. 13 2006 1045 1054
35. M.R. Redinbo, and P.M. Potter Mammalian carboxylesterases: from drug targets to protein therapeutics Drug Discov. Today 10 2005 313 325
36. S.E. Pratt Human carboxylesterase-2 hydrolyzes the prodrug of gemcitabine (LY2334737) and confers prodrug sensitivity to cancer cells Clin. Cancer Res. 19 2013 1159 1168
37. A.C. Antony The biological chemistry of folate receptors Blood 79 1992 2807 2820
38. P. Rajendran Metabolism as a key to histone deacetylase inhibition Crit. Rev. Biochem. Mol. Biol. 46 2011 181 199
39. R. Furumai FK228 (depsipeptide) as a natural prodrug that inhibits class I histone deacetylases Cancer Res. 62 2002 4916 4921
40. D.H. Kim Psammaplin A is a natural prodrug that inhibits class I histone deacetylase Exp. Mol. Med. 39 2007 47 55
41. D.J. Mangelsdorf The nuclear receptor superfamily: the second decade Cell 83 1995 835 839
42. S.M. Sirchia Evidence of epigenetic changes affecting the chromatin state of the retinoic acid receptor beta2 promoter in breast cancer cells Oncogene 19 2000 1556 1563
43. M.A. Carducci Phenylbutyrate induces apoptosis in human prostate cancer and is more potent than phenylacetate Clin. Cancer Res. 2 1996 379 387
44. F.J. Dekker Inhibition of PCAF histone acetyl transferase and cell proliferation by isothiazolones Bioorg. Med. Chem. 17 2009 460 466
45. M. Ghizzoni Reactivity of isothiazolones and isothiazolone-1-oxides in the inhibition of the PCAF histone acetyltransferase Eur. J. Med. Chem. 44 2009 4855 4861
46. R. Wisastra Isothiazolones; thiol-reactive inhibitors of cysteine protease cathepsin B and histone acetyltransferase PCAF Org. Biomol. Chem. 9 2011 1817 1822
47. E.M. Bowers Virtual ligand screening of the p300/CBP histone acetyltransferase: identification of a selective small molecule inhibitor Chem. Biol. 17 2010 471 482
48. K. Balasubramanyam Small molecule modulators of histone acetyltransferase p300 J. Biol. Chem. 278 2003 19134 19140
49. M. Ghizzoni 6-Alkylsalicylates are selective Tip60 inhibitors and target the acetyl-CoA binding site Eur. J. Med. Chem. 47 2012 337 344
50. S. Legartova Basic nuclear processes affect by histone acetyltransferase and histone deacetylase inhibitors Epigenomics 5 2013 1 18
51. X. Luo A selective inhibitor and probe of the cellular functions of Jumonji C domain-containing histone demethylases J. Am. Chem. Soc. 133 2011 9451 9456
52. M. Entin-Meer AN-113, a novel prodrug of 4-phenylbutyrate with increased anti-neoplastic activity in glioma cell lines Cancer Lett. 253 2007 205 214
53. A. Nudelman The role of intracellularly released formaldehyde and butyric acid in the anticancer activity of acyloxyalkyl esters J. Med. Chem. 48 2005 1042 1054
54. T. Reid Phase II trial of the histone deacetylase inhibitor pivaloyloxymethyl butyrate (Pivanex, AN-9) in advanced non-small cell lung cancer Lung Cancer 45 2004 381 386
55. A. Rephaeli The selectivity and anti-metastatic activity of oral bioavailable butyric acid prodrugs Invest. New Drugs 24 2006 383 392
56. G. Kessler-Icekson A histone deacetylase inhibitory prodrug - butyroyloxymethyl diethyl phosphate - protects the heart and cardiomyocytes against ischemia injury Eur. J. Pharm. Sci. 45 2012 592 599
57. N. Tarasenko Histone deacetylase inhibitors: the anticancer, antimetastatic and antiangiogenic activities of AN-7 are superior to those of the clinically tested AN-9 (Pivanex) Clin. Exp. Metastasis 25 2008 703 716
58. K.K. Mann A retinoid/butyric acid prodrug overcomes retinoic acid resistance in leukemias by induction of apoptosis Mol. Cancer Res. 1 2003 903 912
59. J. Yang Conjugate of Pt(IV)-histone deacetylase inhibitor as a prodrug for cancer chemotherapy Mol. Pharm. 9 2012 2793 2800
60. J. Darius Influence of nanoparticles on the brain-to-serum distribution and the metabolism of valproic acid in mice J. Pharm. Pharmacol. 52 2000 1043 1047
61. L. Arabshahi, and F.J. Schmitz Brominated tyrosine metabolites from an unidentified sponge J. Org. Chem. 52 1987 3584 3586
62. I.C. Piña Psammaplins from the sponge Pseudoceratina purpurea: inhibition of both histone deacetylase and DNA methyltransferase J. Org. Chem. 68 2003 3866 3873
63. J.J. Xiao Identification of thiols and glutathione conjugates of depsipeptide FK228 (FR901228), a novel histone protein deacetylase inhibitor, in the blood Rapid Commun. Mass Spectrom. 17 2003 757 766
64. Y. Ying Total synthesis and molecular target of largazole, a histone deacetylase inhibitor J. Am. Chem. Soc. 130 2008 8455 8459
65. N. Shindoh YM753, a novel histone deacetylase inhibitor, exhibits antitumor activity with selective, sustained accumulation of acetylated histones in tumors in the WiDr xenograft model Int. J. Oncol. 32 2008 545 555
66. T. Suzuki Identification of a potent and stable antiproliferative agent by the prodrug formation of a thiolate histone deacetylase inhibitor Bioorg. Med. Chem. Lett. 17 2007 1558 1561
67. T. Suzuki Design, synthesis, and biological activity of folate receptor-targeted prodrugs of thiolate histone deacetylase inhibitors Bioorg. Med. Chem. Lett. 17 2007 4208 4212
68. R.A. Parise A chromatography-electrospray ionization tandem mass spectrometric assay for quantitation of the histone deacetylase inhibitor, vorinostat (suberoylanilide hydroxamicacid, SAHA), and its metabolites in human serum J. Chromatogr. B 840 2006 108 115
69. M. Flipo Hydroxamates: relationships between structure and plasma stability J. Med. Chem. 52 2009 6790 6802
70. M. Thomas Synthesis and biological evaluation of the suberoylanilide hydroxamic acid (SAHA) beta-glucuronide and beta-galactoside for application in selective prodrug chemotherapy Bioorg. Med. Chem. Lett. 17 2007 983 986
71. R. Delatouche Design of pH responsive clickable prodrugs applied to histone deacetylases inhibitors: a new strategy for anticancer therapy Eur. J. Pharm. Biopharm. 85 2013 862 872
72. E. Hockly Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor, ameliorates motor deficits in a mouse model of Huntington's disease Proc. Natl. Acad. Sci. U. S. A. 100 2003 2041 2046
73. E.A. Mohamed Vorinostat with sustained exposure and high solubility in poly(ethylene glycol)-b-poly(dl-lactic acid) micelle nanocarriers: characterization and effects on pharmacokinetics in rat serum and urine J. Pharm. Sci. 101 2012 3787 3798
74. J. Li Biodegradable thermosensitive hydrogel for SAHA and DDP delivery: therapeutic effects on oral squamous cell carcinoma xenografts PLoS ONE 7 2012 e33860
75. J.Y. Kim Tumor vasculature targeting following co-delivery of heparin-taurocholate conjugate and suberoylanilide hydroxamic acid using cationic nanolipoplex Biomaterials 33 2012 4424 4430
76. Y. Ishii Histone deacetylase inhibitor prodrugs in nanoparticle vector enhanced gene expression in human cancer cells Eur. J. Med. Chem. 44 2009 4603 4610
77. J. Datta A new class of quinoline-based DNA hypomethylating agents reactivates tumor suppressor genes by blocking DNA methyltransferase 1 activity and inducing its degradation Cancer Res. 69 2009 4277 4285
78. M. Thomas Synthesis and biological evaluation of glucuronide prodrugs of the histone deacetylase inhibitor CI-994 for application in selective cancer chemotherapy Bioorg. Med. Chem. 16 2008 8109 8116
79. K. Lalji Design, synthesis, and evaluation of novel mutual prodrugs (hybrid drugs) of all-trans-retinoic acid and histone deacetylase inhibitors with enhanced anticancer activities in breast and prostate cancer cells in vitro J. Med. Chem. 51 2008 3895 3904
80. D.M. Hapke Retroviral transfer of deoxycytidine kinase into tumor cell lines enhances nucleoside toxicity Cancer Res. 56 1996 2343 2347
81. C. Stresemann, and F. Lyko Modes of action of the DNA methyltransferase inhibitors azacytidine and decitabine Int. J. Cancer 123 2008 8 13
82. E.-J. Geutjes Deoxycytidine kinase is overexpressed in poor outcome breast cancer and determines responsiveness to nucleoside analogs Breast Cancer Res. Treat. 131 2012 809 818
83. A. Schafer Gemcitabine functions epigenetically by inhibiting repair mediated DNA demethylation PLoS ONE 5 2010 e14060
84. R.A. Fryer Mechanisms underlying gemcitabine resistance in pancreatic cancer and sensitisation by the iMiDTM lenalidomide Anticancer Res. 31 2011 3747 3756
85. J.P. Issa Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-20-deoxycytidine (decitabine) in hematopoietic malignancies Blood 1103 2004 1635 1640
86. M.A. Rudek Pharmacokinetics of 5-azacitidine administered with phenylbutyrate in patients with refractory solid tumors or hematologic malignancies J. Clin. Oncol. 123 2005 3906 3911
87. R.L. Momparler Pharmacology of 5-aza-20-deoxycytidine (decitabine) Semin. Hematol. 142 2005 S9 S16
88. R.E. Notari, and J.L. DeYoung Kinetics and mechanisms of degradation of the antileukemic agent 5-azacytidine in aqueous solutions J. Pharm. Sci. 164 1975 1148 1157
89. C. Champion Mechanistic insights on the inhibition of C5 DNA methyltransferases by zebularine PLoS ONE 5 2010 e12388
90. T. Qin Mechanisms of resistance to 5-aza-20-deoxycytidine in human cancer cell lines Blood 113 2009 659 667
91. D.O. Lau HATs off: selective synthetic inhibitors of histone acetyltransferase p300 and PCAF Mol. Cell 5 2000 589 595
92. J. Wu Bisubstrate inhibitors of the MYST HATs Esa1 and Tip60 Bioorg. Med. Chem. 17 2009 1381 1386
93. M. Cebrat Synthesis and analysis of potential prodrugs of coenzyme A analogues for the inhibition of the histone acetyltransferase p300 Bioorg. Med. Chem. 11 2003 3307 3313
94. Y. Zheng Synthesis and evaluation of a potent and selective cell-permeable p300 histone acetyltransferase inhibitor J. Am. Chem. Soc. 127 2005 17182 17183
95. Y. Zhang A carrier-mediated prodrug approach to improve the oral absorption of antileukemic drug decitabine Mol. Pharm. 10 2013 3195 3202
96. Y. Tsume, and G.L. Amidon Selection of suitable prodrug candidates for in vivo studies via in vitro studies; the correlation of prodrug stability in between cell culture homogenates and human tissue homogenates J. Pharm. Pharm. Sci. 15 2012 433 446
97. Y. Tsume Enhanced absorption and growth inhibition with amino acid monoester prodrugs of floxuridine by targeting hPEPT1 transporters Molecules 13 2008 1441 1454
98. A. Zhanga An HPLC-MS/MS method for simultaneous determination of decitabine and its valyl prodrug valdecitabine in rat plasma J. Chromatogr. B 917 2013 78 83
99. A. Ziemba Development of an oral form of azacytidine: 2,3,5-triacetyl-5-azacytidine Chemother. Res. Pract. 2011 1 9 Article ID: 965826
100. H.M. Byun 2′-Deoxy-N4-[2-(4-nitrophenyl)ethoxycarbonyl]-5-azacytidine: a novel inhibitor of DNA methyltransferase that requires activation by human carboxylesterase Cancer Lett. 266 2008 238 248
101. D.C. Chatterji, and J.F. Gallelli Stabilization of 5-azacytidine by nucleophilic addition of bisulfite ion J. Pharm. Sci. 68 1979 822 826
102. Phiasivongsa, P. and Redkar, S. (2007) Salts of 5-azacytidine. Patent no. EP1788874 A2
103. Z. Yang Folate-based near-infrared fluorescent theranostic gemcitabine delivery J. Am. Chem. Soc. 135 2013 11657 11662
104. R. Karaman Prodrugs of aza nucleosides based on proton transfer reaction J. Comput. Aided Mol. Des. 24 2010 961 970
105. J.M. Collins Suicide prodrugs activated by thymidylate synthase: rationale for treatment and noninvasive imaging of tumors with deoxyuridine analogues Clin. Cancer Res. 5 1999 1976 1981
106. V.F. Patel Novel acid labile COL1 trityl-linked difluoronucleoside immunoconjugates: synthesis, characterization, and biological activity Bioconjug. Chem. 7 1996 497 510
107. E. Leikauf Heterobifunctional trityl derivatives as linking reagents for the recovery of nucleic acids after labeling and immobilization Tetrahedron 51 1995 3793 3802
108. J.M.J. Fréchet Acetals as pH-sensitive linkages for drug delivery Bioconjug. Chem. 15 2004 1254 1263
109. M. Mondon Triazolyl derivatives for acidic release of alcohols Eur. J. Org. Chem. 2011 2111 2119
110. W.G. Chung Stearoyl gemcitabine nanoparticles overcome resistance related to the over-expression of ribonucleotide reductase subunit M1 J. Control. Release 157 2012 132 140
111. S. Zhu The effect of the acid-sensitivity of 4-(N)-stearoyl gemcitabine-loaded micelles on drug resistance caused by RRM1 overexpression Biomaterials 34 2013 2327 2339
112. B.R. Sloat In vitro and in vivo anti-tumor activities of a gemcitabine derivative carried by nanoparticles Int. J. Pharm. 409 2011 278 288
113. M.L. Immordino Preparation, characterization, cytotoxicity and pharmacokinetics of liposomes containing lipophilic gemcitabine prodrugs J. Control. Release 100 2004 331 346
114. C.X. Wang Antitumor effects of polysorbate-80 coated gemcitabine polybutylcyanoacrylate nanoparticles in vitro and its pharmacodynamics in vivo on C6 glioma cells of a brain tumor model Brain Res. 1261 2009 91 99
115. X. Su Lipid-polymer nanoparticles encapsulating doxorubicin and 2′-deoxy-5-azacytidine enhance the sensitivity of cancer cells to chemical therapeutics Mol. Pharm. 10 2013 1901 1909
116. D. Chen EGCG, green tea polyphenols and their synthetic analogs and prodrugs for human cancer prevention and treatment Adv. Clin. Chem. 53 2011 155 177
117. W.J. Lee Mechanisms for the inhibition of DNA methyltransferases by tea catechins and bioflavonoids Mol. Pharmacol. 68 2005 1018 1030
118. M. Fang Dietary polyphenols may affect DNA methylation J. Nutr. 137 2007 223 228S
119. U.P. Singh Resveratrol (trans-3,5,40-trihydroxystilbene) induces SIRT1 and down-regulates NF-kB activation to abrogate DSS-induced colitis J. Pharmacol. Exp. Ther. 332 2009 829 839
120. H. Lu Enzymology of methylation of tea catechins and inhibition of catechol-O-methyltransferase by (-)-epigallocatechin gallate Drug Metab. Dispos. 31 2003 572 579
121. W.-J. Lee Quercetin induces FasL-related apoptosis, in part, through promotion of histone H3 acetylation in human leukemia HL-60 cells Oncol. Rep. 25 2011 583 591
122. K.C. Choi Epigallocatechin-3-gallate, a histone acetyltransferase inhibitor, inhibits EBV-induced B lymphocyte transformation via suppression of RelA acetylation Cancer Res. 69 2009 583 592
123. J.D. Lambert Peracetylation as a means of enhancing in vitro bioactivity and bioavailability of epigallocatechin-3-gallate Drug Metab. Dispos. 34 2006 2111 2116
124. G. Ma Mutual regioselective inhibition of human UGT1A1-mediated glucuronidation of four flavonoids Mol. Pharm. 10 2013 2891 2903
125. H. Van der Woude Identification of 14 quercetin phase II mono- and mixed conjugates and their formation by rat and human phase II in vitro model systems Chem. Res. Toxicol. 17 2004 1520 1530
126. W. Zhu Trans-resveratrol alters mammary promoter hypermethylation in women at increased risk for breast cancer Nutr. Cancer 64 2012 393 400
127. M. Larrosa Effect of a low dose of dietary resveratrol on colonic microbiota, gene expression, inflammation markers, and tissue damage in a DSS-induced colitis rat model J. Agric. Food Chem. 57 2009 2211 2220
128. Y. Chen Curcumin, both histone deacetylase and p300/CBP-specific inhibitor, represses the activity of nuclear factor kappa B and Notch 1 in Raji cells Basic Clin. Pharmacol. Toxicol. 101 2007 427 433
129. Y.J. Wang Stability of curcumin in buffer solutions and characterization of its degradation products J. Pharm. Biomed. Anal. 15 1997 1867 1876
130. M.R. Maradana Targeted delivery of curcumin for treating type 2 diabetes Mol. Nutr. Food Res. 57 2013 1550 1556
131. D.S. Hewings Optimization of 3,5-dimethylisoxazole derivatives as potent bromodomain ligands J. Med. Chem. 56 2013 3217 3227
132. S.-H. Kim Tripartin, a histone demethylase inhibitor from a bacterium associated with a dung beetle larva Org. Lett. 15 2013 1834 1837
133. L. Biasutto Ester-based precursors to increase the bioavailability of quercetin J. Med. Chem. 50 2007 241 253
134. Z. Yu Prodrugs of fluoro-substituted benzoates of EGCG as tumor cellular proteasome inhibitors and apoptosis inducers Int. J. Mol. Sci. 9 2008 951 961
135. L. Biasutto Absorption and metabolism of resveratrol carboxyesters and methanesulfonate by explanted rat intestinal segments Cell. Physiol. Biochem. 24 2009 557 566
136. M. Larrosa Preventive oral treatment with resveratrol pro-prodrugs drastically reduces colon inflammation in rodents J. Med. Chem. 53 2010 7365 7376
137. P. Lu Preparation of curcumin prodrugs and their in vitro anti-tumor activities J. Huazhong Univ. Sci. Technol. Med. Sci. 25 2005 668 670
138. M.M. Yallapu Curcumin nanomedicine: a road to cancer therapeutics J. Drug Target. 20 2012 831 840
139. A.K. Jain Co-encapsulation of tamoxifen and quercetin in polymeric nanoparticles: implications on oral bioavailability, antitumor efficacy, and drug-induced toxicity Mol. Pharm. 10 2013 3459 3474
140. X. Lu Enhanced neuroprotective effects of resveratrol delivered by nanoparticles on hydrogen peroxide-induced oxidative stress in rat cortical cell culture Mol. Pharm. 10 2013 2045 2053
141. A.J. Smith Crystal engineering of green tea epigallocatechin-3-gallate (EGCG) cocrystals and pharmacokinetic modulation in rats Mol. Pharm. 10 2013 2948 2961
142. J.D. Larsen Using the epigenetic code to promote the unpackaging and transcriptional activation of DNA polyplexes for gene delivery Mol. Pharm. 9 2012 1041 1051
143. A. Nishiyama Intracellular delivery of acetyl-histone peptides inhibits native bromodomain-chromatin interactions and impairs mitotic progression FEBS Lett. 582 2008 1501 1507
144. M. Kapoor, and R.A. Siegel Prodrug/Enzyme based acceleration of absorption of hydrophobic drugs: an in vitro study Mol. Pharm. 10 2013 3519 3524
145. V. Mangas-Sanjuán Innovative in vitro method to predict rate and extent of drug delivery to the brain across the blood-brain barrier Mol. Pharm. 10 2013 3519 3524
146. K. Andrieux, and P. Couvreur Nanomedicine as a promising approach for the treatment and diagnosis of brain diseases: the example of Alzheimer's disease Ann. Pharm. 71 2013 225 233
147. B. Chertok Drug delivery interfaces in the 21st century: from science fiction ideas to viable technologies Mol. Pharm. 10 2013 3531 3543